ADAM33 and asthma

Is big beautiful? The continuing story of ADAM33 and asthma
S T Holgate, J W Holloway

Role of ADAM33 in the development and progression of asthma

The gene encoding ADAM33, Disintegrin And Metalloprotease (ADAM) 33 was the first asthma susceptibility gene to be discovered by positional cloning. In 460 families enriched with asthma, linkage analysis using microsatellite markers spaced 1.2 cM apart revealed a region on chromosome 20p13 that carried one or more asthma genes, achieving a Maximum Lod Score (MLS) of 2.24 at 9.99 cM. The addition of further markers at 1.2 cM increased the MLS to 2.94 at 12.1 cM which further rose to 3.93 when bronchial hyperresponsiveness was included in the definition of asthma despite halving the sample size, thereby exceeding the threshold for genome wide significance. Physical mapping, direct cDNA selection, and sequencing of DNA cloned into bacterial artificial chromosomes (BACs) identified 25 candidate genes. Linkage disequilibrium mapping of single nucleotide polymorphisms (SNPs) on 23 genes spanning the peak of linkage together with case-control and family based association analyses revealed that ADAM33 accounted for the linkage signal.

Several features of this initial report raised questions regarding the generalisability of the results. Firstly, although significant evidence for linkage was observed, this region on chromosome 20p had not been identified in previous genome wide screens in asthma. Secondly, the initial publication did not have a truly independent replication sample. Thirdly, no single SNP demonstrated significant association in both the UK and US populations that made up the total sample when these were analysed separately. Finally, no functional data regarding the role of associated SNPs in alteration of gene expression and/or function and in the development of asthma phenotypes were presented.

Since 2002 there have been a number of separate replication studies in diverse ethnic populations. The first by Howard et al examined eight SNPs in the 3' portion of ADAM33 reported in the original study to be associated with asthma in four unique asthma populations comprising African American, US white, US Hispanic, and Dutch white populations. Significant associations with at least one SNP and asthma were found in each of the populations (p = 0.0009–0.04) with multiple SNPs associating with asthma or its partial phenotypes in some of the populations. Further replication has been reported in separate case-control and family based association studies in Germany, Korea, and Japan. However, there are two published studies showing no evidence of association or weak association.

It is therefore timely that, in this issue of Thorax, Blakely and colleagues report the result of a meta-analysis involving eight separate populations totalling 1299 cases and 1665 controls used in case-control association analysis and 4561 families used in transmission disequilibrium tests (TDTs). In both types of analysis several SNPs were significantly associated with asthma. The important point the authors made is that, based on allele frequencies for the ST+7 G allele of 84.9% in the asthmatic population and 79.1% in the controls and an asthma prevalence of 8%, this SNP would potentially contribute to ~50 000 excess asthma cases in the UK population.

What is important to point out is that most case-control and family based association studies looking for disease related genes in complex disorders are statistically underpowered and that far larger sample sizes are needed. Part of the reason for this is the existence of genetic heterogeneity with any one gene varying in its influence over a disease phenotype between populations with differing genetic backgrounds and differing environmental exposures. For example, natural selection may have acted on a disease gene haplotype differentially in different populations as recently described for the IL-4 locus on chromosome 5q31–34. Another example is the NOD2/CARD 15 gene on chromosome 16 which has been associated with Crohn’s disease in some but not all populations. Because a statistical association is not revealed in a particular population irrespective of size does not necessarily mean that the gene in question is not contributing to the phenotype, but the mode of its influence may be complex involving gene-gene or gene-environmental interactions. However, as the number of independent studies increases, it would be valuable to accrue the evidence systematically as was reported for linkage analysis for asthma on chromosome 5 (the Consortium on Asthma Genetics). With the recent establishment of the Network of Excellence for Asthma and Allergy (GA²LEN), there is a unique opportunity to further develop meta-analyses for candidates such as ADAM33. The study by Blakely et al is an excellent example of the power of this approach.

At present the SNPs that cause the dysfunction in ADAM33 predisposing to asthma are not yet clear, although several SNPs (T1, F+1 and ST+7) are coming through in a number of different studies as being associated with asthma. However, because of the very large degree of linkage disequilibrium between many SNPs in ADAM33 so far identified (possibly in excess of 100), genetics alone is unlikely to cast much further light on the disease related variants although new analytical methodologies are being developed. Some clues about how ADAM33 may influence the asthma phenotype are emerging. In 200 Dutch patients with asthma who had regular lung function measurements made over 20 years, the rare alleles of the SNPs S-2, T-1 and T-2 of the ADAM33 gene were associated with a significant excess decline in baseline forced expiratory volume in 1 second (FEV1) of 23.7–30 ml/year. The data imply a role for ADAM33 in airway wall remodelling which is known to contribute to chronic airflow obstruction in moderate to severe asthma. A second study conducted in infants born of allergic/asthmatic parents in Northern England (NAAMAS) has revealed positive associations between SNPs of ADAM33 and increased airway resistance measured by plethysmography at age 3 and again at age 5 years, with the strongest effect seen in the homozygotes. These data support the idea that alterations in the expression or function of ADAM33 is in some way involved in impairing lung function in early life and, as a consequence, increasing the risk of asthma developing.

The initial study as well as others have revealed some of the strongest associations when bronchial hyperresponsiveness (BHR) is incorporated into the asthma phenotype. The cellular provenance of ADAM33 mRNA and
future challenge. We are now entering the new research era of translational science and the rebirth of experimental medicine as a research focus.29


Authors’ affiliations
S T Holgate, J W Holloway, Allergy and Inflammation Research, Division of Infection, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton SO16 6DY, UK
J W Holloway, Division of Human Genetics, School of Medicine, Southampton General Hospital, Southampton SO16 6DY, UK

Correspondence to: Professor S T Holgate, Allergy and Inflammation Research, MP810, Level D, Centre Block, Southampton General Hospital, Southampton SO16 6DY, UK; stholgate@soton.ac.uk

REFERENCES


Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly!

R A Dweik

A possible role for NO in ARDS

Nitric oxide (NO) is endogenously synthesised by nitric oxide synthases (NOS) which convert L-arginine to L-citrulline and NO. Three NOS isoforms (types I, II and III) have been identified and all of them are expressed in the human lung.46 NOS I (nNOS) and III (eNOS) are constitutively expressed in tissues and are dependent on increases in intracellular calcium for enzyme activation while NOS II (iNOS) is an inducible form that is calcium independent (table 1).9 All NOS isoforms require oxygen, NADPH, FAD, FMN, tetrahydrobiopterin, and calmodulin for activity.157 NOS II is found in several types of cells in response to cytokines, endotoxin, or reactive oxygen species, it is continuously expressed in normal human airway epithelium at basal airway conditions.46

Once produced, NO is freely diffusible and enters target cells activating soluble guanylate cyclase to produce guanosine 3′,5′-cyclic monophosphate (cGMP) which mediates most of the physiological effects of NO on smooth muscle including vasodilatation and bronchodilation.21 NO reaction products may also mediate other physiological and pathological functions in the lungs and many other organ systems. Due to the high reactivity, NO participates in a wide variety of reactions at different sites within the cell, lung tissue, extracellular fluids, and intravascular compartments. Primary reactions that may involve NO intracellularly and extracellularly include its reaction with oxygen, superoxide, haemoglobin, another molecule of NO, enzymes containing iron-sulfur centres, heme-containing proteins, and thiol proteins.22 Notably, NO undergoes a direct bimolecular reaction with superoxide (O2−) yielding peroxynitrite (ONOO−) at a rate that is even faster than the dismutation of O2− by superoxide dismutases (SOD), which puts NO at the epicentre of oxidative metabolism and inflammation.

Table 1 Nitric oxide synthase enzymes

<table>
<thead>
<tr>
<th>NOS isoforms</th>
<th>Numerical designation</th>
<th>Other designation</th>
<th>Expression</th>
<th>Regulation</th>
<th>NO output</th>
<th>Chromosome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I</td>
<td>1</td>
<td>nNOS</td>
<td>Constitutive</td>
<td>Calcium/CaM</td>
<td>Low (picomol)</td>
<td>12</td>
</tr>
<tr>
<td>Type II</td>
<td>2</td>
<td>iNOS</td>
<td>Inducible</td>
<td>Calcium/CaM</td>
<td>High (nanomol)</td>
<td>17</td>
</tr>
<tr>
<td>Type III</td>
<td>3</td>
<td>eNOS</td>
<td>Constitutive</td>
<td>Calcium/CaM</td>
<td>Low (picomol)</td>
<td>7</td>
</tr>
</tbody>
</table>

Interestingly, the effect of hypoxia on NO levels in the airway is primarily a result of airway and alveolar oxygen tension rather than vascular oxygen tension.18 19 One proposed mechanism(s) for oxygen regulation of NOS activity is outlined in fig 1. NOS activity during the steady state includes an active cycle (A) that generates NO and an inactive cycle (B) that involves formation and decay of a heme-NO complex. In the active cycle, oxygen binding to ferrous heme (Fe2+) is limiting for enzyme activity. In contrast, resolution of the inactive cycle and entry into the active cycle is oxygen-dependent due to effects on the stability of the heme-NO complex. This includes a reaction between the heme-NO complex and oxygen which results in loss of the heme-NO complex (fig 1).17

The oxygen concentration in intact tissues ranges from 1 to 150 μM,47 26 with the highest levels found in the lung. Airway epithelial cells are unique in their exposure to oxygen since, above a thin layer of epithelial lining fluid, the airway cells are exposed directly to air containing 21% oxygen. Based on oxygen solubility and the low differential oxygen gradient between overlying fluid to intracapillary endoplasmic reticulum (1–2 μM),48 the levels of oxygen in airway epithelial cells may actually approach 260 μM. Thus, the Michaelis constant (KmO2) determined for NOS II (135 μM), but not NOS III (4 μM) or NOS I (400 μM), is well within the physiological range of oxygen concentrations in lung epithelial cells. Importantly, KmO2 for NO synthesis in the intact human lung (190 μM) is similar to NOS II KmO2 in vitro.14 21

REGULATION OF NOS GENE EXPRESSION BY OXYGEN

The immediate effects of short term changes in oxygen concentration on the

Abbreviations: ARDS, acute respiratory distress syndrome; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; KmO2, Michaelis constant; NADPH, reduced nicotinamide-adenine dinucleotide phosphate; NO, nitric oxide; NOS, nitric oxide synthase; O2−, superoxide; ONOO−, peroxynitrite; ROS, reactive oxygen species; SOD, superoxide dismutases.
activity of NOS enzymes are probably due to the effects of oxygen on NOS enzyme kinetics. However, prolonged hypoxia can have significant effects on the gene expression of the different NOS isoforms. These transcriptional effects may vary among species or among organ systems in the same species. For example, while hypoxia produces a progressive decline in constitutive NOS mRNA levels in bovine pulmonary artery endothelial cells, chronic hypoxia upregulates constitutive NOS expression in rabbit heart and rat lung pulmonary arteries. Chronic hypoxia also increases NOS expression and NOS activity in rat carotid bodies.

In this issue of Thorax, Muzaffar et al. describe the effect of hypoxia on the expression of endothelial nitric oxide synthase (NOS III) and gp91phox (the active catalytic subunit of NADPH oxidase), and the formation of superoxide in pig pulmonary artery segments, pulmonary artery smooth muscle cells, and pulmonary artery endothelial cells. They incubated pulmonary artery segments (with and without intact endothelium) and cells (endothelial and smooth muscle cells) in the absence of ambient oxygen for 2 hours and measured the formation of superoxide by ferricytochrome c reduction. They also measured the expression of proteins by Western blotting and immunochemistry. The absence of oxygen in the ambient air promoted the formation of superoxide in the studied tissues and cells. Various enzyme inhibitors were used to determine the source of superoxide production. They also pre-incubated the cells with several inflammatory mediators to determine if they could enhance the effects of hypoxia. A summary of the findings is that hypoxia upregulates NADPH oxidase and NOS III resulting in increased production of superoxide, NO, and peroxynitrite in their system.

A major component missing in the model studied by Muzaffar and colleagues is the role of NOS II. In humans NOS II is continuously expressed in the airway epithelium, is a major source of NO in the lung, and appears to be the most responsive to hypoxia in the physiological range. Due to the free diffusion of NO and the close apposition of airways to pulmonary vessels, endogenous NO production in the airways can have significant effects on the pulmonary vessels. The authors comment on both eNOS (NOS III) and iNOS (NOS II) throughout the paper, but their system does not seem to be appropriate for the study of NOS II which is mainly expressed in the airway epithelium (which the authors did not study) and not in the endothelium or smooth muscle (reported here). The cells they studied did not express NOS II in detectable levels at baseline and that does not change with hypoxia. So, the additional use of NOS II inhibitors does not add much. While the authors emphasise the relevance of their findings to acute respiratory distress syndrome (ARDS), the link is rather speculative. They studied healthy piglets and evaluated their pulmonary artery rings or cells in isolation from the rest of the lung. Although they used pre-incubation with some inflammatory markers as a suggestion as to what happens in ARDS, it would have been more appropriate to study rings from piglets with and without ARDS. The weak link to ARDS, however, does not diminish the relevance of the findings.

NO-SUPEROXIDE INTERACTION

Free radicals/reactive oxygen species (ROS) may be toxic in two ways. They can interact with metal or organic redox centres and promote irreversible oxidation reactions inactivating the target metabolic process, or they can initiate reactions which then become self-sustaining through the generation of propagating radicals. In either case, this can
result in deleterious effects on the cell. The most effective protection against oxidant-mediated tissue damage is to scavenge the initiating radical.11–20 Although NO is itself a radical, many of the same chemical and physical properties of NO that allow it to exert oxidant effects can also result in antioxidant actions. The role of NO as an oxidant or an antioxidant probably depends on the local tissue milieu. In an environment where the oxidant load is low, the highly reactive properties of NO serve as a scavenger of superoxide (O2•−) by rapidly consuming superoxide, NO produces ONOO−, a far less reactive oxidant than the dismutation of O2•− by SOD. By rapidly consuming superoxide, NO undergoing a direct bimolecular reaction with O2•− yielding ONOO− at almost diffusion limited rates (rate constant (k) = 6.7 × 107 M−1s−1).21 The rate constant is over 3.5 times faster than the dismutation of O2•− by SOD. Although NO is itself a radical, many scavenger oxidant species that can be further metabolised to innocuous products like NO3− (fig 2).22–30 Muzaffar and colleagues speculate that the upregulation of two enzymes with opposite effects may represent a protective mechanism to counteract the effect of hypoxia or a pathological mechanism leading to the progression of ARDS. There are no data in their study to favour one explanation over the other. However, based on models in other diseases and on our knowledge of the biology of NO and reactions in the lung, one would suspect that, if hypoxia upregulated NAPDH oxidase without simultaneously upregulating NOS expression, the increased release of superoxide (O2•−) would go unchecked resulting in serious tissue injury. By reacting with superoxide to form peroxynitrite (ONOO−), NO produced by NOS serves as a scavenger of superoxide resulting in a net antioxidant effect (fig 2). The simultaneous upregulation of NOS is therefore probably a protective feature. Although the link to ARDS remains speculative, these findings have potential implications for a wide variety of lung diseases from asthma to pulmonary hypertension.12–15, 15, 15–15, 15–20

REFERENCES


www.thoraxjnl.com

Thorax first published as 10.1136/thx.2004.032698 on 24 March 2005. Downloaded from http://thorax.bmj.com on August 1, 2021 by guest. Protected by copyright.
Early diagnosis of lung cancer

Symptoms and the early diagnosis of lung cancer

S S Birring, M D Peake

Significant delays remain in the diagnosis of lung cancer

Lung cancer is the leading cause of cancer death in the western world, resulting in nearly 30,000 deaths in England and Wales in 2002.1 Advances in the management of breast, cervical, and prostate cancer have led to improved survival rates, whereas mortality from lung cancer has remained largely unchanged.2 Even the best reported 5 year survival rates for lung cancer are only 10–15%3,4 and, in England, in patients diagnosed between 1993 and 1995 the survival rate was only 5.3% at 5 years and 22% at 1 year.5

This high mortality is very largely a consequence of patients presenting late when the cancer is already locally advanced or has disseminated. Around 80% of patients with lung cancer have stage III or IV disease at presentation, therefore excluding them from potentially curative surgical resection.6 Detection of the tumour at an earlier stage leads to an improved prognosis, patients presenting with stage I A non-small cell lung cancer and undergoing surgical resection having a 5 year survival of around 60%.7

Patients can (and usually do) live with lung cancer for many years before it becomes apparent. Early lung cancer is largely asymptomatic and internalisation of tumours means patients are not alerted by obvious physical changes. It takes around 8 years for a squamous cell carcinoma, for example, to reach a size of 30 mm when it is most commonly diagnosed so, by the time symptoms arise, the risk of metastasis is considerable.8 Once symptoms appear they are often ignored by patients, delaying the diagnosis and treatment even further. The reasons for patient delay in diagnosis are poorly understood.

Lung cancer can present with a wide range of symptoms, the most common being cough, haemoptysis, chest and shoulder pain, dyspnoea, hoarseness, weight loss, anorexia, fever, weakness, and bone pain.9 Guidelines based on this pattern of symptoms have been developed10 and stress that the physician needs to be alert to the possibility of lung cancer in patients with such symptoms, particularly if they are persistent and occur in those at higher risk of lung cancer—for example, smokers and ex-smokers, especially those over the age of 50 and with chronic airflow obstruction. Unfortunately, symptoms of lung cancer are largely non-specific and recognition of new symptoms is more difficult in the presence of co-existing respiratory disease such as chronic obstructive pulmonary disease. In addition, the evidence base for these guidelines (and the forthcoming updated NICE version) is weak and contains no data on the predictive value of symptoms or symptom complexes for the presence or absence of lung cancer in a primary care based population.

In this issue of Thorax Corner and colleagues present the findings of an exploratory retrospective interview study commissioned by the Department of Health’s policy research programme investigating patient delays in cancer diagnosis.11 Detailed interviews were carried out in 22 patients after diagnosis but before treatment to obtain a pre-diagnosis symptom history. This history was compared with primary care and hospital records. Cough and dyspnoea were found to be the most common symptoms among a wide range reported. All patients experienced at least one new symptom before diagnosis. Although the symptoms were reported as a persistent change in health status, they were not interpreted as being serious at their onset. The median interval from the initial change in health status and the symptom prompting the first visit to the general practitioner was found to be 7 months, with a further average delay of 5 months to diagnosis. Interestingly, there were no significant differences in delays to diagnosis according to operability of the tumour.

The findings of the study by Corner et al, although preliminary, are of interest and confirm that there are significant patient related delays for the diagnosis of lung cancer, longer than those previously reported. Jensen et al12 reviewed the time elapsed from symptoms to medical attention reported in 16 studies and found a wide variation from 7 days to 6 months. This wide range of patient delay times is likely to be a result of many factors, including socioeconomic, cultural and health care differences. The reasons why patients did not interpret their symptoms as serious or seek medical attention sooner are not reported by Corner et al and need further investigation. The most plausible explanation for this is that, while reported symptoms were new, they were too non-specific—especially in the context of co-existing respiratory disease—to raise alarm. A limitation of the data reported by Corner et al is that there is no objective validation of the presence and timing of symptoms reported before the first consultation with the GP. Patients, with hindsight of the diagnosis, may look for explanations and re-examine past events which we recognise in other clinical situations are often false. Prospective studies of the specificity and predictive value of reported symptoms for the diagnosis of lung cancer and their prevalence in high risk individuals would be required to answer these questions, although such studies are complex, expensive, and long term. Other factors that may contribute to patient delays in diagnosis include denial, fear, guilt, other psychosocial issues, poor public health education, and issues relating to access to health care. The fact that the patients in this study did not interpret the early changes as potentially serious may also mean that they were reluctant to bother their GPs with what they considered “trivial” complaints. Bowen et al13 studied factors influencing patient delays and found that male patients had longer delays, over half of all patients needed encouragement from family or friends to see their GP, and 75% were not aware of the significance of their symptoms and had not received any advice about them. Future studies also need to explore how patients respond to changes in health status, why patients with lung cancer appear to have such relatively little contact with their GP, and whether improved public awareness of lung cancer symptoms and easier access to a wider variety of sources of healthcare advice could contribute to achieving earlier diagnosis with a consequent improvement in survival.

Attempts should be made to develop public health education programmes promoting awareness of lung cancer, a process which needs to be accompanied by the presentation of a more positive image of lung cancer, stressing the fact that early diagnosis saves lives rather than perpetuating the negative image that the current prognosis for the majority of patients is so poor.
Early symptom recognition in lung cancer will only be worthwhile if it improves outcomes for patients, especially survival. Christensen et al.15 found that, for patients with operable lung cancer (stage I/II), the interval between the trigger symptom initiating contact with the healthcare system and the time of operation was significantly shorter than the time between the trigger symptom and the decision not to operate for patients with stage III/IV disease. In contrast, Myrdal et al.16 found the time from onset of symptoms to treatment was shorter in patients with stage IV lung cancer (median 3.4 months) than in those with stage I/II disease (median 5.5 months). This is likely to result from the fact that patients with advanced disease had more severe symptoms and signs and received more rapid treatment. The current study by Corner et al.17 did not find differences in patient delay times according to the stage of lung cancer, but the numbers studied were insufficient to answer this question. Studies investigating the effect of hospital delays in diagnosis and treatment on prognosis similarly report conflicting results. Comparison of the data in these studies is, however, made difficult by the differing definitions of patient delays and clinical differences of patient groups studied.18–19

Because of the non-specific nature of the symptoms in question and the fact that a paradigm shift in the behaviour of the population at most risk of developing lung cancer is highly unlikely, attempts at making major progress on early referral at a population level based on symptoms alone seem very unlikely to be successful. Other methods of early detection therefore need to be energetically explored to lower the stage at presentation in lung cancer. Screening is an attractive option because there is a welldefined high risk popula-
tion and the potential for curative surgery in early disease. Radiological screening has been the most studied. The screening trials of the 1970s/80s with chest radiography were deemed negative,20 but the advent of faster spiral and multiple slice CT scanners have led to a renewed interest. Preliminary studies of low dose CT screening show promise and formal trials are underway.21 The demonstration of benefits of screening programmes on the overall survival statistics of the studied population is essential before widespread use of this method is adopted. Currently, the improved survival benefits of screening are not known and interpretation of published studies is made difficult since no randomised trial has yet been reported and issues such as lead time and over-diagnosis bias add to the complexity of interpretation.22 The natural history of malignant nodules as small as 5 mm detected on CT scans is not well described and even nodules only 10 mm in size containing 109 cells represent a fairly late stage in the disease process, considering that at death lung cancer tumours typically have 1012 cells.23 The survival benefit of any screening programme must also outweigh the risks related to managing false positive nodules. The optimum strategy for the management of small lesions identified on screening has not been determined.

Another potential screening tool is advanced sputum cytology, enhanced by molecular genetics, immunohistochemistry, including the monoclonal antibody staining of antigens expressed by lung cancer cells.23–24 Autofluorescence bronchoscopy may complement cytology with the potential for the detection of metaplasia and carcinoma in situ in bronchial mucosa.25 A multimodality approach may be required to optimise early detection and management of lung cancer from screening programmes and early attempts at this approach look promising.26

While efforts consequent upon the National Cancer Plan27 and the Cancer Services Collaborative have helped to reduce hospital delays, the study by Corner et al reminds us that significant delays remain in the diagnosis of lung cancer before the patient ever gets into secondary care. While this is clearly an important area for future research, it is probable that—in the absence of a major advance in treatment or a significant further reduction of cigarette consumption—some form of screening is the intervention most likely to have a major impact on the current poor survival statistics, and it is vital that the major funders of national research programmes grasp this difficult nettle as soon as possible.

Reference

doi: 10.1136/thx.2004.032698

Authors’ affiliations

S S Birring, M D Peake, Thoracic Oncology Unit, Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK

Correspondence to: Dr M D Peake, Thoracic Oncology Unit and Institute for Lung Health, Department of Respiratory Medicine, Glenfield Hospital, Leicester LE3 0QP, UK; mick.peake@uhl-tr.nhs.uk

References


3 SEER. www.seer.gov


Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification

J J Egan, F J Martinez, A U Wells, T Williams

Application of a classification based on simple lung function testing in IPF

For many years the idiopathic pulmonary fibrosis (IPF) community has debated the merits of the histopathological classification of idiopathic interstitial pneumonia (IIP). The ATS/ERS consensus statement identifies the importance of histological categories of usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP). Furthermore, it emphasises that IPF is the clinical correlate of UIP. Despite the recognition of the importance of histological characterisation, surgical biopsy rates vary considerably. Most clinicians do not subject their patients to surgical biopsy, despite the potential prognostic benefit of detailed histological evaluation, because many patients are elderly and have significantly impaired lung function and other medical co-morbidities resulting in a potentially high mortality rate. In addition, HRCT scanning provides diagnostic data of high sensitivity and specificity for the diagnosis of IPF with acceptable interobserver variability.

Meanwhile, the chronic obstructive pulmonary disease (COPD) and lung transplantation communities have applied simple but pragmatic classification systems. Bronchiolitis obliterans syndrome (BOS), for example, has been subject to a clinical grading system reflecting the degree of impairment of lung function following lung transplantation. The emergence of a classification based on simple lung function testing occurred because of the difficulties in obtaining adequate tissue for the diagnosis of obliterative bronchiolitis. This is comparable to the situation in IPF where tissue is also difficult to obtain. The success of the classification of BOS is reflected by the publication of an updated version.

The global initiative for COPD (GOLD) is another example of a consensus classification based on simple lung function testing. GOLD provides a staging system ranging from an “at risk” category to a severe disease category. Based on simple lung function testing, it is reproducible and has facilitated the identification of patients with COPD. Furthermore, it has enabled worldwide harmonisation of clinical and experimental research studies in COPD.

Recent publications relating to lung function, focusing specifically on IPF, provide a similar opportunity. The histological classification proposed by Katzenstein and endorsed by the ATS/ERS consensus statement potentially allows for the development of a staging system based on simple and widely available evaluation techniques. The aim of such a classification would not be to supersede the histological classification but rather to build upon it.

The aim of this review is therefore to discuss the potential of a grading system for IPF based solely on simple static lung function studies. For judging disease severity we sought a parameter that identified patients with impaired survival, defined as less than 2 years. For judging disease progression we sought lung function changes which identified patients at increased risk of mortality.

HISTOLOGICAL CLASSIFICATION AND LUNG FUNCTION

The absence of broad agreement on the interpretation of lung function testing in IPF reflects the variability in published data on the subject (table 1). Impaired survival has been associated with a variety of findings including no relationship with lung function, increased ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC ratio), reduced total lung capacity (TLC), change in FVC/carbon monoxide transfer factor (TLCO) after 1 year (table 1). Formally a critical confounding factor influencing the interpretation of lung function was the failure to distinguish between histological subsets in IPF. Consequently, early published data on lung function have been limited by the absence of focus on specific histological subgroups. Recent publications have therefore focused on lung function data specifically in the context of UIP and NSIP, allowing a consistent theme to emerge (table 1). A PubMed literature search was performed to identify peer reviewed manuscripts relating to lung function testing in IPF published in 1998–2004. This period was chosen because it reflects the clinical impact of the characterisation of patients based on histological subsets as described by Katzenstein et al in 1998.

LUNG FUNCTION AND DISEASE SEVERITY

A global view of historical lung function data emphasises that a poor outcome is associated with “low” lung function. Schwartz et al highlighted the fact that reduced lung function was associated with limited survival. In a study of 74 individuals who had undergone lung biopsy, univariate analysis showed that there was a greater hazard of death with lower % predicted FVC and lower % predicted TLC. However, clinicians require a specific threshold in the context of disease severity. The study by Gay et al emerged as a key publication in the context of the methodology used for appraising the influence of lung function. In contrast to historical studies which reported group differences in survival and hazard ratios, they applied for the first time receiver operator characteristic (ROC) curve estimates. ROC state the probability that a diagnostic criterion selects a disease subject correctly rather than a non-disease subject. In the context of lung function, ROC curves express the ability of a variable to discriminate between death and/or survival. However, despite the application of ROC analysis by Gay et al, no lung function variable identified risk of death (table 1). This likely reflects the efforts to study well characterised patients, resulting in a relatively small number of subjects in the study.

DISEASE SEVERITY: ADVANCED AND LIMITED DISEASE

Acknowledging the need for a specific threshold value for estimating disease severity, recent data suggest that severity of disease can be categorised as advanced or limited disease on the basis of lung function. Extending the study by Gay et al by using ROC analysis, Mogulkoc et al focused on lung function in the context of transplant referral. This study targeted a well characterised group of 115 patients with IPF aged 45–65 years. A total of 12 variables influencing survival were significant on univariate regression analysis. A multivariate stepwise regression analysis identified only % predicted TLC and HRCT fibrosis as independent predictors of 2-year survival. ROC analysis of %
predicted TLco gave an area of 0.8 (CI 0.7 to 0.9) and HRCT fibrosis score gave an area of 0.86 (CI 0.77 to 0.95). It was shown that a gas transfer factor of <39% of predicted combined with HRCT scores had an 80% sensitivity and specificity for predicting death within 2 years. This allowed the observation of a simple measure of TLco to be associated with a specific limited time frame of survival. Identification of a threshold value associated with increased mortality serves as the basis for a distinction between advanced and limited disease (fig 1).

The concept of advanced IPF was corroborated by the work of Latsi et al. In a retrospective study of 104 patients with a histologically confirmed diagnosis, determinants of early mortality at presentation and mortality after 6 months of follow up were studied. In patients dying within 2 years of presentation, the median TLco was 39% of the predicted value. These authors present patients with advanced disease as an "early mortality" group in whom physiologic impairment is reached, mortality is increased.

As lung function is the primary investigation performed by pulmonologists, patients may therefore be defined as having advanced disease (TLco <39% of predicted), allowing the potential identification of patients with poor early survival. Although FVC is predictive of survival in univariate modelling, it does not maintain its effect in multivariate analysis. The severity of IPF is therefore best graded by TLco estimation. For patients with limited disease (TLco >40% of predicted), longer survival is more likely. It is in this latter group that serial lung function studies have particular prognostic value.

**LUNG FUNCTION AND DISEASE PROGRESSION**

ROC curve analysis highlights the fact that TLco is superior to FVC for evaluating disease severity. In contrast, a change in FVC may be the most reliable simple lung function variable to highlight disease progression. When appraising lung function studies of disease progression in IPF, three points deserve consideration: the coefficient of variation of the test, the baseline from which the change occurs, and the time scale used to determine change.

The intertest variation has been widely studied. A 10% change in FVC is required accurately to reflect a change in vital capacity. Using TLco requires a change of 15% or more. Consequently, the baseline from which change occurs is vital to observe. Because many patients with IPF present with a TLco of <39% of predicted, a further 15% fall from baseline is difficult to document. Individuals require adequate pulmonary reserve to exhibit a change in that parameter. Inadequate reserve may explain why a significant proportion of patients fail to show evidence of lung function progression. Patients with limited disease or adequate pulmonary reserve therefore lend themselves to evaluation of disease progression.

The time required to observe a change in lung function is also critical. As the mean survival of some groups of patients may be as low as 2.5 years, a prolonged period of observation of, for example, 1 year biases a study towards patients with favourable survival and limited disease. Hanson et al were the first to study the change in lung function over 1 year. They studied 58 patients and evaluated the influence of a 10% change in FVC and a 20% change in TLco. This cohort had favourable characteristics including a mean age of 55 years and a mean survival of 88 months. The mean survival of patients exhibiting a change (24% of the total) in FVC was 2.5 years. The mean survival of patients exhibiting a change was also 2.5 years in TLco (22% of the total).

Acknowledging this, two recent publications progress the strategy described by Hanson et al. Firstly, Collard et al, in a study of 81 patients with UIP, evaluated change in lung function over both 6 and 12 months. The median

---

Table 1: Summary of lung function studies in IPF

<table>
<thead>
<tr>
<th>Author</th>
<th>Subset</th>
<th>N</th>
<th>Age (years)</th>
<th>FVC</th>
<th>TLco</th>
<th>(Survival months)</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schwartz</td>
<td>No</td>
<td>38</td>
<td>62</td>
<td>67%</td>
<td>46%</td>
<td>NA</td>
<td>Decreased TLC/TLco associated with dyspnoea</td>
</tr>
<tr>
<td>Schwartz</td>
<td>No</td>
<td>74</td>
<td>67</td>
<td>62%</td>
<td>44%</td>
<td>60</td>
<td>Increased FEV₁/FVC ratio</td>
</tr>
<tr>
<td>Hanson</td>
<td>No</td>
<td>58</td>
<td>59</td>
<td>61%</td>
<td>42%</td>
<td>88</td>
<td>Reduced mortality</td>
</tr>
<tr>
<td>Erbes</td>
<td>No</td>
<td>99</td>
<td>53</td>
<td>89%</td>
<td>46%</td>
<td>41</td>
<td>Increased mortality</td>
</tr>
<tr>
<td>Hubbard</td>
<td>No</td>
<td>244</td>
<td>69</td>
<td>78%</td>
<td>49%</td>
<td>34</td>
<td>Reduced TLC</td>
</tr>
<tr>
<td>Guy</td>
<td>Yes</td>
<td>38</td>
<td>54</td>
<td>UIP 69 %</td>
<td>UIP 50%</td>
<td>26</td>
<td>Reduced mortality</td>
</tr>
<tr>
<td>Maguillac</td>
<td>Yes</td>
<td>115</td>
<td>55</td>
<td>UIP 72 %</td>
<td>UIP 49%</td>
<td>50</td>
<td>UIP 46%</td>
</tr>
<tr>
<td>Wells</td>
<td>Yes</td>
<td>197</td>
<td>62</td>
<td>UIP 68 %</td>
<td>36%</td>
<td>22</td>
<td>UIP 46%</td>
</tr>
<tr>
<td>Latsi</td>
<td>Yes</td>
<td>104</td>
<td>55</td>
<td>UIP 72 %</td>
<td>NSIP 73%</td>
<td>NSIP 41%</td>
<td>NSIP 56</td>
</tr>
<tr>
<td>Collard</td>
<td>Yes</td>
<td>81</td>
<td>61</td>
<td>UIP 67 %</td>
<td>UIP 52%</td>
<td>51</td>
<td>UIP 46%</td>
</tr>
<tr>
<td>Flaherty</td>
<td>Yes</td>
<td>80</td>
<td>62</td>
<td>UIP 72 %</td>
<td>NSIP 71%</td>
<td>NSIP 48%</td>
<td>69 (total group)</td>
</tr>
</tbody>
</table>

Subset refers to whether the authors specified the histological subset studied.

**ADVANCED DISEASE**

TLco <39% predicted

Refer for transplant if appropriate candidate

**LIMITED DISEASE**

TLco >40%

**PROGRESSIVE DISEASE**

FVC fall >10%

**Figure 1** A classification of IPF based on simple lung function criteria. TLco, carbon monoxide transfer factor; FVC, forced vital capacity.
survival of the patients subject to 6 month evaluation was 4.8 years and 6.2 years for those studied at 12 months. The mean TLC of the group was 52% of predicted. Changes in TLC % predicted, FVC % predicted, and TLC % predicted over 6 months predicted survival of these, the change in FVC % predicted was the best predictor. Flaherty et al.20 studied 109 patients, 80 of whom had UIP and 29 had NSIP. The mean TLC of the group was 50% of predicted. 32% of patients had a fall of >10% in FVC and 49% of patients remained within 10% of baseline. On multivariate analysis, controlling for histological subgroups and baseline lung function, a change in FVC over 6 months was an independent risk factor for mortality. Both studies included patients with preserved TLC in the region of 50% of predicted.21 22

Changes in TLC are an alternative measure of disease progression. Latsi et al.21 observed a higher mortality in patients with a decline in TLC at 6 and 12 months. Whether trends were quantified numerically or categorically. However, repeat TLC measurements can be difficult to standardise, explaining the need for a greater change in TLC than in FVC in order to categorise deterioration. In the study by Latsi et al., serial TLC trends had only a minimal prognostic advantage over serial FVC trends and the analysis included a significant subset of patients with advanced disease. In the recently published interferon gamma-1b treatment study only 14% of 300 patients with a mean TLC of 37% were defined as having disease progression based on a 15% change in TLC (Bill Bradford, personal communication).23

Therefore the authors favour classification of disease progression based on change in FVC at 6 months rather than 1 year because this allows the early identification of progressive disease. However, in patients with limited disease the potential value remains of re-evaluating progression at 1 year, as demonstrated by Flaherty and Latsi.21 22 Re-evaluation at 12 months may be particularly important in the context of a “marginal” decline in FVC of 5–10%, which may reflect either measurement variation or genuine disease progression. Thus, the definition of disease progression using change over 6 months should not obscure the need to refine prognostic evaluation at 1 year and at least 6 monthly intervals thereafter.

**REFERENCES**

EDITORIAL


Online First

Online First in Thorax

J A Wedzicha, S L Johnston, D M Mitchell

We are pleased to announce that Thorax is about to start posting all original articles on its website in an Online First section (http://www.thoraxjnl.com) shortly after acceptance and before the papers are published in the print version of the journal. Although the time from acceptance to publication in Thorax is relatively short, this initiative is a welcome contribution. An Online First programme was introduced by the British Medical Journal in December 2003, followed by other specialist journals from the BMJ Publishing Group. All original articles have also been posted early after acceptance by the American Journal of Respiratory and Critical Care Medicine for some time.

Authors want their research studies to be published as soon as possible after acceptance so that their important scientific and clinical findings can be cited and incorporated into practice. However, there are inevitable delays between acceptance of an article and its appearance in the print version of the journal. Online First in Thorax will allow research work to be available much faster to the research community; manuscripts that have not yet been finally edited by our technical editor will be posted on the website.

With the introduction of Online First, authors will be asked to check their papers carefully after acceptance and before the manuscript is posted. The paper will be identified by its unique number—the digital object identifier (DOI)—which will appear at the top of the pdf and will be used to cite the article. Articles published Online First will also be indexed by PubMed early after online publication and will be available when searching for papers using search engines such as PubMed and Google. The final version of the article will be edited by the technical editor and then printed with its DOI number. All versions of the paper will be linked online and will be available to readers.

We hope that the introduction of Thorax Online First will be welcomed by researchers, clinicians, and readers. We encourage you all to log on frequently and to visit the new site to view the recently accepted papers in the journal. Articles can be accessed using the Thorax Online First icon on the Thorax home page. With progress in electronic publishing, important advances in respiratory medicine can now be implemented much more quickly to the benefit of patients all over the world.

doi: 10.1136/thx.2005.043190

Authors’ affiliations

Correspondence to: Professor J A Wedzicha, Thorax Editorial Office, BMA House, Tavistock Square, London WC1H 9JR, UK, J.a.wedzicha@qmul.ac.uk

REFERENCES